Evidence map›Paper›PMID 38114565›Full record

ReviewThe Journal of antibiotics2024

Cephalosporin resistance, tolerance, and approaches to improve their activities.

Alison H Araten, Rachel S Brooks, Sarah D W Choi, Laura L Esguerra, Diana Savchyn, Emily J Wu, Gabrielle Leon, Katherine J Sniezek, Mark P Brynildsen

Abstract readReview
PubMed Publisher
In one paragraph

Review in The Journal of antibiotics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Siderophore cephalosporins.EcoSal Plus · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Alison H Araten *Department of Molecular Biology, Princeton University, Princeton, NJ, USA.
Rachel S Brooks *Department of English, Princeton University, Princeton, NJ, USA.
Sarah D W Choi *Department of Molecular Biology, Princeton University, Princeton, NJ, USA.
Laura L Esguerra *Department of Chemical and Biological Engineering, Princeton University, Princeton, NJ, USA.
Diana Savchyn *Department of Chemical and Biological Engineering, Princeton University, Princeton, NJ, USA.
Emily J Wu *Department of Chemical and Biological Engineering, Princeton University, Princeton, NJ, USA.
Gabrielle LeonDepartment of Chemical and Biological Engineering, Princeton University, Princeton, NJ, USA.
Katherine J SniezekDepartment of Chemical and Biological Engineering, Princeton University, Princeton, NJ, USA.
Mark P BrynildsenDepartment of Molecular Biology, Princeton University, Princeton, NJ, USA. mbrynild@princeton.edu.ORCID 0000-0001-5707-8894
Princeton University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cephalosporins comprise a β-lactam antibiotic class whose first members were discovered in 1945 from the fungus Cephalosporium acremonium. Their clinical use for Gram-negative bacterial infections is widespread due to their ability to traverse outer membranes through porins to gain access to the periplasm and disrupt peptidoglycan synthesis. More recent members of the cephalosporin class are administered as last resort treatments for complicated urinary tract infections, MRSA, and other multi-drug resistant pathogens, such as Neisseria gonorrhoeae. Unfortunately, there has been a global increase in cephalosporin-resistant strains, heteroresistance to this drug class has been a topic of increasing concern, and tolerance and persistence are recognized as potential causes of cephalosporin treatment failure. In this review, we summarize the cephalosporin antibiotic class from discovery to their mechanisms of action, and discuss the causes of cephalosporin treatment failure, which include resistance, tolerance, and phenomena when those qualities are exhibited by only small subpopulations of bacterial cultures (heteroresistance and persistence). Further, we discuss how recent efforts with cephalosporin conjugates and combination treatments aim to reinvigorate this antibiotic class.

Indexed as

Cephalosporin ResistanceGram-Negative Bacterial InfectionsAnti-Bacterial AgentsCephalosporinsHumansMonobactamsNeisseria gonorrhoeaeAnti-Bacterial AgentsCephalosporinsMonobactams

Identifiers

PMID38114565
OpenAlexW4389939957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.